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Abstract Glycogen synthase kinase-3 is involved in diverse
functions including insulin signalling and development. In a
number of substrates, phosphorylation by glycogen synthase
kinase-3 is known to require prior phosphorylation at a Ser in the
+4 position relative to its own phosphorylation site. Here we have
used synthetic peptides derived from a putative glycogen synthase
kinase-3 site in the Drosophila translation initiation factor
eIF2BO to investigate the efficacy of residues other than Ser(P)
as priming residues for glycogen synthase kinase-3L and its
Drosophila homologue Shaggy. glycogen synthase kinase-3L
phosphorylated peptides with Ser(P) and Thr(P) in the priming
position, but peptides with Tyr(P), Thr, Glu or Asp were not
phosphorylated. The Vmax for the Thr(P) peptide was three times
higher than that of the Ser(P) peptide. These data suggest that
glycogen synthase kinase-3 is unique among phosphate-directed
kinases. The priming site specificity of Shaggy is similar to that
of mammalian glycogen synthase kinase-3L. This unpredicted
efficacy of Thr(P) in the priming position suggests that there may
be other unidentified substrates for these kinases.
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1. Introduction
Glycogen synthase kinase-3 (GSK-3) was ¢rst identi¢ed by
virtue of its ability to phosphorylate residues in skeletal
muscle glycogen synthase (GS) which are important in the
regulation of the activity of this enzyme by insulin [1]. Sub-
sequent studies have revealed that it has other substrates
which are implicated in the control of other cell functions,
such as protein synthesis (the e-subunit of initiation factor
eIF2B) and development (L-catenin) [1], and that GSK-3 is
acutely regulated by insulin and other agents [1,2]. Insulin
rapidly inactivates GSK-3 and leads to the phosphorylation
of a conserved serine in the N-terminus of GSK-3. This is Ser9
in the L-isoform and Ser21 in the K-isoform of GSK-3 [3,4].
Since phosphorylation by GSK-3 inhibits both GS and eIF2B
[5,6], the inactivation of GSK-3 in response to insulin pro-
vides a mechanism through which insulin may activate both
glycogen and protein synthesis. A number of studies have
shown that the signalling events which lie upstream of
GSK-3 involve phosphatidylinositol 3-kinase [7^9] and that
the protein kinase responsible for the phosphorylation and
inactivation of GSK-3 is protein kinase B (PKB, [10^12]).
Recent studies have shown that insulin brings about the de-
phosphorylation of the O-subunit of mammalian eIF2B at
Ser540, the site phosphorylated by GSK-3 [6].
GSK-3 is also known to play key roles in the regulation of
development in a wide range of species from insects to mam-
mals [1]. Shaggy, the structural homologue of GSK-3 in Dro-
sophila, plays multiple roles in development [1,13,14] and its
mammalian homologue GSK-3L can complement a number
of functions of the Shaggy gene in this organism [14]. Genetic
evidence for paracrine signalling during the Drosophila epithe-
lium development has indicated the involvement of Shaggy in
the transduction of the Wingless signal [15]. Wingless acts
through Dishevelled (whose function is currently unknown)
to inactivate Shaggy, allowing Armadillo (the Drosophila ho-
mologue of L-catenin) to initiate the formation of sheet epi-
thelium. Biochemical evidence from studies on Wingless in
mouse 10T1/2 ¢broblasts has con¢rmed the role of Shaggy/
GSK-3 in the Wingless signalling pathway and have also sug-
gested that protein kinase C (PKC) lies upstream of Shaggy/
GSK-3 [16].
Besides GS and eIF2BO, a number of other substrates for
GSK-3 have been identi¢ed including the type 1 phosphatase
subunit RGI [17], ATP-citrate lyase [18] and the transcription
factor CREB (the cAMP response element binding protein
[19]). Phosphorylation of this group of substrates requires
prior phosphorylation of the C-terminal serine residue in the
motif Ser-Xaa-Xaa-Xaa-Ser, where the more N-terminal ser-
ine residue is the target for GSK-3 [5,20]. However, it is not
known whether phosphorylated residues other than Ser(P)
(e.g. Thr(P), Tyr(P)) can serve this so called ‘priming’ function
or whether other acidic residues (Asp, Glu) can do so. In the
case of acidophilic, phosphate-directed protein kinases such as
casein kinase-1 and -2 and Golgi apparatus casein kinase, at
least some of these residues can substitute for Ser(P) and in
some cases are actually better than Ser(P) [21^23].
Recent searching of Drosophila databases has revealed a
genomic sequence that appears to be the homologue of eIF2-
BO. This sequence (669 amino acids) shows similarity through-
out its entire sequence to mammalian eIF2BO (716 amino
acids) and Gcd6p (712 amino acids), the homologue of eIF2-
BO in Saccharomyces cerevisiae (identity at the amino acid
level being 30 and 25% to these two proteins, respectively).
The Drosophila sequence contains a serine at the position
corresponding to Ser540 (the target for GSK-3) in the rabbit
sequence. However, the possible priming site is occupied by a
Thr rather than a Ser which is found in all the known mam-
malian eIF2BO sequences (Table 1), raising the question
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whether residues other than Ser(P), particularly Thr(P), can
function in the C-terminal priming position to facilitate the
phosphorylation by GSK-3. In this study, we have examined
the e⁄cacy of such residues in priming the phosphorylation
by mammalian GSK-3L and Shaggy, using synthetic peptides.
2. Materials and methods
2.1. Chemicals and biochemicals
Chemicals and biochemicals were obtained from BDH (Poole, Dor-
set, UK) and Sigma-Aldrich (Gillingham, Dorset, UK), unless stated
otherwise. [Q-32P]ATP was obtained from Amersham and phosphocel-
lulose (P81) and DEAE cellulose (DE81) paper were obtained from
Whatman. Recombinant GSK-3L was kindly provided by Dr. A. Pa-
terson (Dundee, MRC Protein Phosphorylation Unit). Dr. J.R.
Woodgett (Ontario Cancer Institute) kindly provided a vector (pAC
5.1a) encoding Drosophila Shaggy with a hexa-His tag.
2.2. Synthetic peptides
The peptides T, Tp, Sp, E, D and Yp were synthesised by an
automated peptide synthesiser ABI 431-A (Applied Biosystems) on
4-hydroxymethyl-phenoxymethylcopolystirene-1% divinylbenzene-res-
in (1.04 mmol/g). The synthesiser was equipped for using 9-£uorenyl-
methoxycarbonyl chemistry [24] and our own 2-(1H-benzotriazole-1-
yl)-1,1,1,3,3 tetramethyluronium hexa£uorophosphate/N-hydroxyben-
zotriazole protocol (see details in [25]) in a 0.05 mmol scale.
The incorporation of phospho-residues of Thr, Ser and Tyr was
performed according to a building block approach [26] using the
following Fmoc phospho-amino acid derivatives: Fmoc-Ser(PO(ben-
zyl)OH, Fmoc-Thr(PO(benzyl)OH and Fmoc-Tyr(PO3H2)OH. Cleav-
age of peptides from the resin and side chain deprotection was carried
out by treatment of the peptidyl resin with tri£uoroacetic acid(TFA)/
anisole/ethanedithiol/ethylmethylsul¢de (95:3:1:1). The presence of
the benzyl protecting group on phosphoresidues of serine and threo-
nine, a mixture of TFA/triisopropylsilane/water (95:2.5:2.5), was pre-
ferred.
The crude peptides were puri¢ed by high performance liquid chro-
matography (HPLC) on a preparative reverse phase column Prep
Nova-Pak HR C18, 6 m, 25U10 mm (Waters). The analytical
HPLC and MALDI-TOF mass spectrometry analysis of the puri¢ed
peptides showed a correct sequence and a purity of 95%.
2.3. Production of Shaggy protein
Drosophila melanogaster Schneider cells were transfected using the
calcium phosphate procedure [27,28]. 3 days post-transfection, 3 ml of
cells (at a density of 6U106 cells/ml) were harvested in lysis bu¡er
containing 20 mM HEPES-KOH (pH 7.6), 0.27 M sucrose, 1 mM
EDTA, 0.5% Triton X-100, 0.5 mM sodium orthovanadate, 0.1 mM
DTT and protease inhibitors, leupeptin, aprotinin, pepstatin and
benzamidine (all at 1 Wg/ml) and 0.1 mM PMSF. The lysates were
then incubated for 1.5 h at 4‡C with Talon Metal A⁄nity Resin
(Clontech, CA, USA) to bind the recombinant His-tagged Shaggy.
Beads were then washed with lysis bu¡er and used as a source of
Shaggy in assays using synthetic peptides.
2.4. Phosphorylation assays
Peptide phosphorylation assays were carried out essentially as de-
scribed [14,29]. More speci¢cally, phosphorylation was performed at
30‡C in a 20 Wl assay containing the various peptides (0.4 mM unless
otherwise indicated), 16 mM HEPES-KOH (pH 7.5), 2 mM MgCl2,
80 mM KCl, 0.1 mg/ml BSA, 25 WM ATP and 0.8 WCi [Q-32P]ATP
(speci¢c activity ranged between 1500 and 4000 cpm/pmol). 32 mU of
GSK-3L (0.028 Wg) was used in each assay, where one unit is the
amount of protein kinase transferring 1 nmol of phosphate/min to
the standard substrate [30]. Reactions involving the phosphorylation
of peptides by Shaggy were performed in a similar manner. To ter-
minate reactions, samples were mixed with 5 Wl of 0.5 M EDTA.
Reaction mixtures containing basic peptides (SRAGS and SRAGSp)
were spotted onto P81 paper and washed ¢ve times for 5 min with 1%
(v/v) phosphoric acid. In the case of acidic peptides (all others), re-
action mixtures were spotted onto DE81 paper and washed ¢ve times
for 5 min in a solution containing 50 mM Tris-HCl (pH 7.5) and 100
mM NaCl as described [31]. Incorporation of 32P into the peptides
was determined using the Cerenkov method. Kinetic analysis of the
peptide phosphorylation was calculated from Eadie-Hofstee plots, us-
ing regression analysis of double reciprocal plots constructed from
initial rate measurements.
3. Results
In a large proportion of the substrates for GSK-3, there is
an almost absolute requirement for the prior phosphorylation
of the more C-terminal serine residue in the motif Ser-Xaa-
Xaa-Xaa-Ser in order for GSK-3 to phosphorylate its own
target serine [5,20]. Our recent work on the role of GSK-3
in the regulation of the translation initiation factor eIF2B
from mammals has indicated that this protein is no exception
to this general rule [30]. Synthetic peptide substrates based on
the mammalian eIF2BO sequence (see Table 1 for details of
the peptides) have previously been used to demonstrate the
requirement for Ser(P) in the +4 position for phosphorylation
by GSK-3 [32]. The Ser(P) at the +4 position is therefore said
to be a ’priming’ phosphorylation site [20,32,33]. In agreement
with previous data [30], peptides containing Ser(P) were read-
ily phosphorylated (Fig. 1A).
The discovery, through database searching, of a Drosophila
homologue of eIF2BO with a potential GSK-3 site (where the
priming residue is a threonine) prompted us to investigate the
e⁄ciency of other residues in this position. To test whether
Thr(P) could act to promote a GSK-3L-mediated phosphoryl-
ation, we synthesised the peptide EDDEDASRAVTPLPDD
and two variants, ‘Sp’ and ‘Tp’, in which a Ser(P) or a Thr(P),
respectively, was incorporated during synthesis (see Table 1).
Phosphorylation of these peptides by GSK-3L was assessed
over time (Fig. 1B). The peptide T, containing a non-phos-
phorylated threonine at position +4, was not phosphorylated
signi¢cantly. In contrast, peptide TP was readily phospho-
rylated by recombinant GSK-3L (Fig. 1B), illustrating that
Thr(P) can act as an e⁄cient recognition determinant for
GSK-3, at least in the case of this peptide. Three other pep-
tides were also synthesised and tested for their ability to prime
GSK-3L (shown in Table 1). These peptides, containing a Glu
(potentially resembling Thr(P), peptide E in Table 1), an Asp
(resembling Ser(P), peptide D in Table 1) or Tyr(P) (peptide
Yp in Table 1) at the priming position, failed to undergo
phosphorylation upon incubation with recombinant GSK-3L
(Fig. 1B). Thus GSK-3L can recognise the motif Ser-Xaa-
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Table 1
Synthetic peptides used in this study
Peptides derived from D. melanogaster eIF2BO (accession number
AL021086)
Peptide name Sequence
T E D D E D A S R A V T P L P D D
Tp E D D E D A S R A V TP P L P D D
Sp E D D E D A S R A V SP P L P D D
E E D D E D A S R A V E P L P D D
D E D D E D A S R A V D P L P D D
Yp E D D E D A S R A V YP P L P D D
Peptides derived from eIF2BO (accession number U19516) ([6])
SRAGS R R A A E E L D S R A G S P Q L
SRAGS(P) R R A A E E L D S R A G SP P Q L
The GSK-3 phosphorylation site (rat) or putative GSK-3 (D. mela-
nogaster) phosphorylation site is shown in bold and the priming site
or variants introduced at that site are italicised. A P indicates a phos-
phorylated residue.
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Xaa-Xaa-Ser(P)/Thr(P), suggesting that there may be other
substrates for this kinase containing Thr at the priming site.
The results in Fig. 1B suggest that GSK-3L phosphorylates
a peptide with Thr(P) in the priming position at a higher rate
than that seen with the corresponding peptide with Ser(P) in
the same position. In order to compare directly the e⁄ciencies
of peptides Tp and Sp as substrates for GSK-3L, we carried
out a detailed kinetic analysis using these two peptides. As
shown in Table 2, the Vmax of peptide Tp (768 pmol 32P
incorporated/min/Wg) was higher than that of peptide Sp
(249 pmol 32P incorporated/min/Wg), thus con¢rming that
peptide substrate Tp is phosphorylated by GSK-3L at a higher
rate. The 3-fold di¡erence between peptides Tp and Sp is
similar to that seen in Fig. 1B. The Km values calculated for
peptides Tp (40.0 WM) and Sp (39.2 WM) indicate that the
a⁄nity of GSK-3L for these substrates is essentially the
same (Table 2). The kinetic values for peptide SRAGSp
were also calculated as a control and were found to be similar
to those reported previously [30]. Taken together, these results
showed, in this case, that the peptide with a Thr(P) in the
priming position is a more e⁄cient substrate for GSK-3L
than the peptide with a Ser(P) in the priming position. Further
analysis will be required to determine whether or not this is
true for other substrates.
These results clearly show that a Thr(P) in the critical posi-
tion of the Drosophila eIF2BO derived peptide, TP, is able to
prime the substrate for the phosphorylation by recombinant
mammalian GSK-3L. If Drosophila eIF2B is a physiological
substrate for GSK-3 in fruit £ies, Shaggy would have to be
able to phosphorylate peptides containing Thr(P). However,
the speci¢city determinants for Shaggy-mediated phospho-
rylation have not been tested before. To test this, His-tagged
Shaggy was expressed in and puri¢ed from Drosophila
Schneider cells. All ¢ve variants of the Drosophila-derived
peptide were incubated with His-tagged Shaggy and their
phosphorylation was assessed (Fig. 2). Here, we show for
the ¢rst time, biochemically, that Shaggy requires a priming
phosphorylation, four residues C-terminal of the target serine,
and that this priming residue can be either a Ser(P) or Thr(P),
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Fig. 1. Time courses of the phosphorylation of synthetic peptides based on (A) mammalian and (B) Drosophila eIF2BO by mammalian GSK-
3L. The peptides are designated as described in Table 1. Experimental conditions were as described in Section 2. The data are representative of
at least three separate experiments.
Table 2
Kinetic analysis for the phosphorylation of peptides Tp, Sp and
SRAGSp by mammalian GSK-3L
Peptide Km S.D. Vmax S.D. Vmax/Km
(WM) (+/3) (pmol/min/Wg) (+/3)
Tp 40.0 4.7 786 39.2 19.6
Sp 39.2 2.4 249 42.0 6.3
SRAGSp 95.3 40 206 5.6 2.1
Experimental conditions are described in Section 2 with the exception
that the peptide concentrations were varied. Average values and S.D.
from three or more experiments are shown.
Fig. 2. Phosphorylation of synthetic peptides based upon Drosophila
eIF2BO by Drosophila His-tagged Shaggy. The peptides are desig-
nated as described in Table 1. The experimental conditions are de-
scribed in Section 2. The data show an average of the results from
two independent experiments.
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as is the case with mammalian GSK-3L [6], indicating that
Drosophila eIF2B is likely to be a physiological substrate for
Shaggy. Interestingly, the same characteristics of phosphoryl-
ation observed for the recombinant GSK-3L with peptides Tp
and Sp were seen with Shaggy. Again, the peptide with a
Ser(P) in the priming position was phosphorylated less e⁄-
ciently than that with a Thr(P) in the same position. As ob-
served for mammalian GSK-3L, peptides T, E and Yp were
not phosphorylated.
4. Discussion
Hierarchical phosphorylation, where phospho-acceptor sites
are speci¢ed by the phosphorylation of other adjacent speci¢c
residues, has been described for a number of other protein
kinases including the casein kinase from the Golgi apparatus
of lactating mammary gland (GEF-CK), casein kinases-1 and
-2 and the acidophilic protein tyrosine kinase Syk [23,34]. The
order of e¡ectiveness of di¡erent residues in the priming posi-
tion for these kinases is shown in Table 3. As indicated, only
the tyrosine-directed kinase Syk phosphorylates peptides con-
taining a Thr(P) more e⁄ciently than those with a Ser(P).
Both GSK-3L and Shaggy also phosphorylate the peptide
based on D. melanogaster eIF2BO with a Thr(P) at a higher
rate than when a Ser(P) is in the same position, however
Tyr(P) and Glu are not recognised. This pattern di¡erentiates
GSK-3L and Shaggy from all the other phosphate-directed
protein kinases studied to date.
An important unsolved question concerning the identity of
the protein kinase responsible for priming both GSK-3L and
Shaggy remains. The observation that the priming residue is
followed by a proline suggests that members of the MAP
kinase or cyclin-dependent kinase families may be responsible,
since proline-directed kinases tend to phosphorylate Thr as
readily as, if not better than, Ser [35].
In this study, we have shown phosphorylation of the prob-
able Drosophila homologue of eIF2BO by Shaggy in vitro,
implying a possible role for Shaggy in the regulation of eIF2-
BO in vivo. The involvement of Shaggy in at least two impor-
tant developmental pathways, the Wingless [13] and Notch
[14] signalling cascades, leads to speculation about the role
of the translation initiation factor eIF2B in the Drosophila
development through modulation of translation of speci¢c
transcripts. There is a well-established precedent for this in
budding yeast (GCN4 [36,37]). In our future work, we aim
to address whether the regulation of translation, by means of
Shaggy-mediated phosphorylation of eIF2Be, is involved in
development by studying the phosphorylation and control of
Drosophila eIF2B.
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